KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesChange in Working CapitalExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet Equity Issued and RepurchasedNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Novartis Ag (NVS) over the last 17 years, with Q4 2025 value amounting to -$981.0 million.

  • Novartis Ag's Gains from Investment Securities fell 616.88% to -$981.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$2.6 billion, marking a year-over-year decrease of 1346.32%. This contributed to the annual value of -$2.6 billion for FY2025, which is 1346.32% down from last year.
  • Latest data reveals that Novartis Ag reported Gains from Investment Securities of -$981.0 million as of Q4 2025, which was down 616.88% from -$366.0 million recorded in Q3 2025.
  • In the past 5 years, Novartis Ag's Gains from Investment Securities ranged from a high of -$260.0 million in Q3 2022 and a low of -$1.1 billion during Q4 2023
  • For the 5-year period, Novartis Ag's Gains from Investment Securities averaged around -$589.1 million, with its median value being -$558.0 million (2024).
  • As far as peak fluctuations go, Novartis Ag's Gains from Investment Securities surged by 6217.44% in 2022, and later crashed by 22724.55% in 2023.
  • Quarter analysis of 5 years shows Novartis Ag's Gains from Investment Securities stood at -$883.0 million in 2021, then skyrocketed by 62.17% to -$334.0 million in 2022, then plummeted by 227.25% to -$1.1 billion in 2023, then increased by 15.46% to -$924.0 million in 2024, then fell by 6.17% to -$981.0 million in 2025.
  • Its Gains from Investment Securities stands at -$981.0 million for Q4 2025, versus -$366.0 million for Q3 2025 and -$675.0 million for Q2 2025.